Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide.The book explores the rising global prevalence of obesity and diabetes, emphasizing the urgent need for innovative solutions
R.G.P.2/152/46
Evaluating the efficacy of sodium glucose cotransporter-2 inhibitors in management of obstructive sleep apnea
Thomas RH, Luthin DR
By causing glycosuria as their primary mechanism of action, they create a persistent bacterial growth medium in the urinary tract
In patients, liraglutide is administered daily with a target dose of 1.8 mg s.c
US$ 25.34
US$ 20.10
US$ 29.46
US$ 28.67
.png.jpg)
US$ 28.62
US$ 23.39
US$ 25.68
